| 0 (0%) | 02-21 18:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.55  |
1-year : | 40.5 |
| Resists | First : | 32.15 |
Second : | 34.68 |
| Pivot price | 30.74 |
|||
| Supports | First : | 28.05 | Second : | 23.34 |
| MAs | MA(5) : | 29.47 |
MA(20) : | 31.46 |
| MA(100) : | 31.49 |
MA(250) : | 25.89 |
|
| MACD | MACD : | -1 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 11.6 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 35.43 | Low : | 17.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GMAB ] has closed above bottom band by 23.1%. Bollinger Bands are 31.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.5 - 29.68 | 29.68 - 29.85 |
| Low: | 28.52 - 28.73 | 28.73 - 28.93 |
| Close: | 28.97 - 29.28 | 29.28 - 29.57 |
Fri, 20 Feb 2026
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Yahoo Finance UK
Thu, 19 Feb 2026
William Blair Maintains Genmab(GMAB.US) With Buy Rating - 富途牛牛
Wed, 18 Feb 2026
GMAB: HC Wainwright & Co. Raises Price Target to $40.00, Maintai - GuruFocus
Wed, 18 Feb 2026
Genmab A/S (NASDAQ:GMAB) Q4 2025 Earnings Call Transcript - Insider Monkey
Wed, 18 Feb 2026
Does Genmab’s 2026 Outlook and Abkinley Win Reset the Bull Case for Genmab (CPSE:GMAB)? - simplywall.st
Tue, 17 Feb 2026
Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 616 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 9,910 (K) |
| Shares Short P.Month | 11,500 (K) |
| EPS | 2.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 93.41 |
| Profit Margin | 41.1 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 13.3 % |
| Return on Equity (ttm) | 29.4 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 5.89 |
| Sales Per Share | 6.25 |
| EBITDA (p.s.) | 2.38 |
| Qtrly Earnings Growth | 107.5 % |
| Operating Cash Flow | 1,370 (M) |
| Levered Free Cash Flow | 956 (M) |
| PE Ratio | 12.84 |
| PEG Ratio | 0 |
| Price to Book value | 0.31 |
| Price to Sales | 4.68 |
| Price to Cash Flow | 13.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|